Last reviewed · How we verify
18F-αvβ6-BP
18F-αvβ6-BP is a Radiopharmaceutical imaging agent Small molecule drug developed by Julie L. Sutcliffe, Ph.D. It is currently in Phase 1 development. Also known as: Image Enhancement Agent.
A fluorine-18 labeled radiotracer that binds to αvβ6 integrin for PET imaging of cancer and fibrotic diseases.
18F-αvβ6-BP is a small molecule used in clinical trials for various types of cancer, including breast carcinoma, colorectal carcinoma, and lung carcinoma. It is being studied as a potential intervention for metastatic malignant neoplasms in the breast and colon.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | 18F-αvβ6-BP |
|---|---|
| Also known as | Image Enhancement Agent |
| Sponsor | Julie L. Sutcliffe, Ph.D |
| Drug class | Radiopharmaceutical imaging agent |
| Modality | Small molecule |
| Phase | Phase 1 |
Mechanism of action
18F-αvβ6-BP is a radiolabeled peptide that selectively binds to the αvβ6 integrin receptor. This integrin is upregulated in multiple cancers and fibrotic conditions, making it a valuable biomarker for disease detection and monitoring through PET imaging.
Approved indications
Common side effects
Key clinical trials
- PET/CT Imaging in COVID-19 Patients (EARLY_PHASE1)
- Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer (PHASE1)
- First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-αvβ6-BP CI brief — competitive landscape report
- 18F-αvβ6-BP updates RSS · CI watch RSS
- Julie L. Sutcliffe, Ph.D portfolio CI
Frequently asked questions about 18F-αvβ6-BP
What is 18F-αvβ6-BP?
How does 18F-αvβ6-BP work?
Who makes 18F-αvβ6-BP?
Is 18F-αvβ6-BP also known as anything else?
What drug class is 18F-αvβ6-BP in?
What development phase is 18F-αvβ6-BP in?
Related
- Drug class: All Radiopharmaceutical imaging agent drugs
- Manufacturer: Julie L. Sutcliffe, Ph.D — full pipeline
- Also known as: Image Enhancement Agent
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing